Skip to Content

What does Ocaliva treat?

Answers (1)

Official Answer by 1 Jun 2016

Ocaliva (generic name: obeticholic acid) was given accelerated FDA approval in May 2016 and is combined with ursodeoxycholic acid (UDCA) in adults with an inadequate UDCA response or as the only treatment in adults unable to tolerate UDCA. Ocaliva is a first-in-class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC), previously known as biliary cirrhosis. FXR is a nuclear receptor expressed in the liver and intestine and a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways.

PBC is a rare liver disease that primarily results from autoimmune destruction of the bile ducts that transport bile acids out of the liver, resulting in cholestasis. Cholestasis occurs when the flow of bile from the liver decreases. Symptoms of cholestasis include itching, dark-colored urine, stomach pain, yellowing of the eyes or skin (jaundice), and pale-colored stools.

Ocaliva is the first new treatment for PBC in nearly 20 years.

Votes: +0 free discount card

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What are the active ingredients in Qtern?

Posted 5 Jul 2017 1 answerFAQ by

What is the Siliq REMS Program?

Posted 5 Jul 2017 1 answerFAQ by

What type of drug is Emflaza?

Posted 5 Jul 2017 1 answerFAQ by

What is Parsabiv used to treat?

Posted 5 Jul 2017 1 answerFAQ by

Is Xyzal available over-the-counter?

Posted 5 Jul 2017 1 answerFAQ by